NESP

Anaemia associated w/ chronic renal failure (CRF). Anaemia & reduction of transfusion requirements in patients w/ non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy. Anaemia w/ myelodysplastic syndrome.

CRF patient & those w/ non-myeloid malignancies receiving chemotherapy Lowest dose that will gradually increase Hb conc to approach a target of not >12 g/dL; rate of Hb increase should not exceed 1 g/dL in any 2-wk period. Correction of anaemia Initially 0.45 mcg/kg SC/IV as a single inj once wkly. May be increased by approx 25%. Further increases may be made at 4-wk intervals until the desired response is attained. Maintenance of Hb conc Patient on dialysis & not on dialysis May be dosed wkly or once every 2 wk at the titrated dose to maintain target Hb. For dose adjustment to maintain target Hb, individual dose may be adjusted at 4-wk intervals until the appropriate Hb level is achieved. Conversion from recombinant human erythropoietin (r-HuEPO) to NESP Initial SC dose: Divide the total wkly r-HuEPO SC dose (u/wk) by 200. Initial IV dose: Divide the total wkly r-HuEPO IV dose (u/wk) by 240. Patient w/ non-myeloid malignancies receiving chemotherapy Initially 2.25 mcg/kg once wkly as single SC inj. Dose adjustment in cancer patients: If Hb approaches 12 g/dL, reduce dose by approx 25-50%. If Hb is >12 g/dL, temporarily w/hold dose & re-initiate when Hb decreases to 11 g/dL at 25-50% below the previous dose. Anaemia w/ myelodysplastic syndrome Adult 240 mcg as a single SC inj once wkly. Dose should be decreased in view of the degree of anaemic symptoms & patient's age.

Hypersensitivity. Known sensitivity to products derived from mammalian cells. Uncontrolled HTN.

Haematopoietic Agents / Supportive Care Therapy

B03XA02 - darbepoetin alfa ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.

POM